Suboptimal outcomes of first-line chemotherapeutic regimens for advanced stages of classical Hodgkin lymphoma
Background. Despite high efficacy of chemotherapy in Hodgkin lymphoma (HL), a substantial proportion of patients (about 20 %) still experience relapse or refractory disease. This study was aimed to analyze efficacy and toxicity of most widely-used chemotherapy regimens for advanced-stage HL at a single center. Materia...